Chronic myeloid leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• ABL1 12
• TP53 1
• JAK 1
• AKT 0
• IDH 4
• ERK 0
• FLT3 2
• PI3K 0
• JNK 0
• STAT3 0
• BCL-2 2
• CD19 1
• HSP90 0
• KIT 1
• PDGFR 0
• CSF1R 2
• HDAC 0
• HIF-1 0
• IL-1 2
• MAPK 0
• PPAR 0
• AMPK 0
• CD123 0
• CD38 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• mTOR 0
• NLRP3 0
• NRF2 0
• RAS 0
• RUNX1 0
• BTK 0
• CD20 0
• CD22 0
• CD33 0
• CD40 0
• CD47 1
• CTLA-4 0
• CXCR4 0
• G6PD 0
• GLP-1 0
• IL-15 0
• IL-6 1
• KRAS 0
• MEK 1
• MYC 0
• NPM1 0
• NRAS 0
• PD-1 0
• PRMT5 0
• PTEN 0
• SGLT2 0
• SIRT1 0
• TIM-3 0
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  The Role of Cell Competition in Shaping the Clonal Structure of Hematopoiesis

  Washington University· Saint Louis, United States· US$465,749 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · K99

  The Epitranscriptomic-Microtubule Axis as a Novel Mechanism of Ponatinib induced Cardiotoxicity

  University of Illinois at Chicago· Chicago, United States· US$139,113 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R21

  Interferon-γ in combination with donor leukocyte infusion to treat relapsed acute myeloid leukemia and myelodysplastic syndromes after haploidentical donor stem cell transplantation

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$408,829 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · F31

  Role of ABL kinases in regulating DNA damage repair and transcription-replication conflicts in SCLC tumors

  Duke University· Durham, United States· US$43,742 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · F30

  From Resistance to Innovation: Towards Countering Asciminib Resistance and Designing Next-Generation Allosteric Inhibitors against CML

  State University New York Stony Brook· Stony Brook, United States· US$42,647 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon 2020) · ERC-STG

  Functional Interrogation of Non-coding DNA Sequences in leukemia development and drug resistance (FIND-seq)

  St. Anna Kinderkrebsforschung Gmbh· Wien, Austria· EU contribution €1,784,000· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

6 of 51 running projects, newest first. Listed amounts together: US$33.5m + €1.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Novartis Pharmaceuticals· Updated 13 Jan 2026

  “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Novartis Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 2
• Gene Expression Profiling 6
• Sequence Analysis, RNA 2
• Exome Sequencing 1
• Proteomics 5
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 13
• Xenograft Model Antitumor Assays 19
• Magnetic Resonance Imaging 4
• Machine Learning 3
• Cohort Studies 9
• Genome-Wide Association Study 3

• Cross-scale genetic, molecular, and cellular triangulation prioritizes ACSL5 as a T3-responsive candidate linking hypothyroidism liability to anemia.

  Front Endocrinol (Lausanne), Oct 2026

• Chronotype and sleep duration in relation to leukaemia subtypes: a two-sample Mendelian randomization analysis.

  Hematology, Feb 2026

• Causal effects of vitamin D on leukemia risk: insights from two-sample Mendelian randomization analysis.

  Nutr Hosp, Apr 2025

See which targets of this disease your abstract mentions, and go to the people working on them.